Blauvelt A, Mehlis S, Vanaclocha F, Vender R, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S. Secukinumab provides greater 52-week sustained relief from dermatology-related quality of life impact on clothing choice and sexual function than ustekinumab. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.

Abstract not available at this time.

Share on: